Journal
BIOORGANIC CHEMISTRY
Volume 77, Issue -, Pages 579-585Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bioorg.2018.02.001
Keywords
Enantiomers; Lignans; A beta aggregation; Molecular docking; Molecular dynamics; Alzheimer's disease
Funding
- National Natural Science Foundation of China [81502954]
- Project of Innovation Team of Liaoning of P.R. China [LT2015027]
Ask authors/readers for more resources
To develop potential agents for slowing the progression of Alzheimer's disease, two pairs of new enantiomeric lignans, including a couple of rarely 8',9'-dinor-3',7-epoxy-8,4'-oxyneolignanes named (7S, 8S)- and (7R, 8R)-pithecellobiumin A (1a/1b) and a pair of 2',9'-epoxy-arylnaphthalenes named (7R, 8R, 8'R)- and (7S, 8S, 8'S)-pithecellobiumin B (2a/2b) were separated by chiral high performance liquid chromatography (HPLC). Their planar structures were elucidated by spectroscopic data analyses. The absolute configurations were determined by comparing of experimental and calculated electronic circular dichroism (ECD). The inhibitory activity on A beta aggregation of all optical pure compounds was tested by ThT assay. Interestingly, enantiomeric inhibitors la (62.1%) and lb (81.6%) exhibited different degrees of anti-A beta aggregation activity. However, 2a (65.4%) and 2b (68.4%) showed similar inhibition rate. The different inhibition profiles were explained by molecular dynamics and docking simulation studies. (C) 2018 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available